Daraxonrasib Approval Gives Pancreatic Cancer Its First RAS Drug

A long-standing barrier falls

For about forty years, RAS was the cancer target drug developers could see but couldn't hit. On August 26, 2026, the FDA approved a drug that hits it. Revolution Medicines' daraxonrasib, sold as Rasonque, is a once-daily oral tablet. It is approved for adults with metastatic pancreatic adenocarcinoma who have had at least one prior systemic therapy or who cannot receive multiagent systemic therapy.211 The FDA calls it a first-in-class targeted therapy. The American Association for Cancer Research says it is the first pan-RAS inhibitor approved for any cancer type, because it is not limited to one specific mutation.216

The approval matters for patients, and it also says something about how the FDA now works. Daraxonrasib was reviewed under the Commissioner's National Priority Voucher (CNPV) pilot program. That is the same fast lane the agency used earlier this year for two high-profile weight-loss drugs.325 Pancreatic cancer and obesity are very different problems, but in 2026 they have gone through the same regulatory channel. Putting the two side by side shows both what the program can do and where its limits are.

What the trial showed

The approval rests on RASolute 302, a randomized, open-label, multicenter Phase 3 trial. It enrolled 500 adults whose metastatic pancreatic ductal adenocarcinoma had progressed after a fluoropyrimidine- or gemcitabine-based regimen. They received either daraxonrasib or the investigator's choice of chemotherapy.3 Median overall survival was 13.2 months on daraxonrasib and 6.7 months on chemotherapy, which works out to roughly a 60% lower risk of death.23 In other words, the drug about doubled survival compared with chemotherapy. Coverage across outlets consistently describes it that way.51419

Response rates point the same way. Confirmed objective responses were 31.6% with daraxonrasib versus 11.2% with chemotherapy in the overall population. In patients with RAS G12 mutations, the figures were 33.2% versus 11.8%.13 Patients also appeared to tolerate the drug better. Grade 3 or higher adverse events occurred in 61.8% of daraxonrasib patients and 69.6% of chemotherapy patients. Side effects led 1.2% of daraxonrasib patients to stop treatment, compared with 11.2% on chemotherapy.2 Rash and stomatitis were the most common reasons for dose reductions.18 The label also carries warnings for gastrointestinal perforation, interstitial lung disease or pneumonitis, and embryo-fetal toxicity.6

The reported numbers differ slightly from outlet to outlet. Several give median progression-free survival as 7.2 months versus 3.6 months for the overall population.214 Others give 7.3 versus 3.5 months, which corresponds to the RAS G12-mutant subgroup assessed by blinded independent central review.613 The differences come from which population is being reported, not from conflicting data. Patients with RAS G12 mutations made up 91.8% of participants, so the two sets of figures are nearly identical.2

The voucher behind the speed

The review was unusually fast. The FDA accepted the application on July 22, 2026, and said it expected the review to take one to two months.13 The approval came 6.5 months before the user-fee deadline. Angelo de Claro, director of the FDA's Oncology Center of Excellence, cited that timing as proof of the agency's commitment to speed.1318 Daraxonrasib also had Breakthrough Therapy, Orphan Drug, and Priority Review designations. Before approval, the FDA allowed an expanded access protocol in May.313

Obesity drugs were the program's first showcase. On April 1, Eli Lilly's orforglipron (Foundayo) became the first new molecular entity approved under CNPV. The decision came 50 days after filing and 294 days before its user-fee date, making it the fastest approval of a new molecular entity since 2002.21 Novo Nordisk's higher-dose Wegovy HD went first, approved March 19 after 54 days. Those two were the program's fourth and fifth approvals.25 The FDA launched the voucher in June 2025. It covers national priorities including unmet medical need, innovative breakthrough therapies, and affordability, and it uses a collaborative review modeled on a tumor board.24

The obesity approvals showed the program could handle drugs headed for very large markets. Daraxonrasib shows it can also handle a hard-won oncology drug for a lethal disease. One analyst argued in PharmExec that the first group of voucher recipients gain a compounding advantage. Their regulatory risk and timing uncertainty drop, and Revolution Medicines' valuation rose after its voucher was awarded.3 Our view is that daraxonrasib makes the strongest case so far that the program is about more than politically visible weight-loss drugs. The survival data were strong enough that an earlier approval was easy to defend.

The two drugs are priced very differently

The obesity comparison is starkest on price. Rasonque's wholesale acquisition cost is $39,800 for a 30-day supply.6 Foundayo's listed prices include $25 a month with commercial coverage, $50 a month through a Medicare bridge program, and a $149 self-pay starting price.25 The gap partly reflects the markets: one drug is meant for huge numbers of patients, the other is an orphan oncology drug. Still, affordability is one of the priorities the voucher program names.24 So far, the program's own approvals show that a fast review does not by itself deliver a lower price.

Insurance coverage will matter a great deal at that price. Memorial Sloan Kettering notes that FDA approval generally means many insurers and Medicare will cover or subsidize a new therapy.14 PharmExec expects the drug's durability, results in specific mutation subgroups, and long-term tolerability as a chronic oral treatment to shape formulary reviews.3

A label wider than the trial

The most contested part of the approval is the label, not the data. The indication does not require a RAS mutation or a companion diagnostic.11 Investigators at Sylvester Comprehensive Cancer Center said the label was broader than they expected, because the trial itself required KRAS mutation testing.19 Supporters point to survival gains in the overall population, not only in the RAS G12 group, as the basis for dropping the mutation requirement.18 Revolution Medicines' chief executive, Mark Goldsmith, praised the label for supporting real-world clinical decisions.11

The second part of the indication is harder to defend. It covers patients who are not candidates for multiagent systemic therapy, including some who have never received prior systemic treatment. RASolute 302 only studied previously treated patients who were well enough to enroll.12 A Nature Reviews Clinical Oncology commentary describes it as an imprecise label for a precision medicine and reports that critics call that clause not evidence-based.8 Europe has been more cautious. An ESMO guideline update recommended daraxonrasib monotherapy after chemotherapy progression only in patients with RAS G12-mutated disease and an ECOG performance status of 0 or 1.13

Public coverage has added some confusion of its own. One consumer health outlet said the approval covers patients whose tumors have a specific KRAS mutation.15 The company's announcement and other patient-facing coverage say clearly that no particular mutation is required.1112 The label text supports the second reading.

Questions that remain

There is one methodological caveat. PharmExec warned that the open-label design could bias progression-free survival assessments unless they were reviewed blind.3 Other trade coverage reports that PFS was in fact assessed by blinded independent central review, at least in the RAS G12 population, which addresses much of that concern.13 Overall survival, the primary measure here, cannot be biased by who reads the scans.

Clinicians are clear that this is a major advance but not a cure. Memorial Sloan Kettering's Eileen O'Reilly, who led the trial at her institution, says patients "live better for longer."14 Dana-Farber's Brian Wolpin calls it the biggest therapeutic advance in metastatic pancreatic cancer in decades.17 PanCAN's Anna Berkenblit pointed out that a pill can be less burdensome than intravenous chemotherapy.6 Because patients take it at home, nurses and pharmacists will take on more responsibility for monitoring adherence and side effects.57

The next step is earlier treatment. RASolute 303 is testing daraxonrasib alone and with gemcitabine plus nab-paclitaxel as first-line therapy. RASolute 304 is testing it after surgery in patients with resected disease.13 Competing drugs are also moving forward. In August, Erasca's pan-RAS molecular glue ERAS-0015 received fast track designation, and Lilly's KRAS G12C inhibitor olomorasib received breakthrough designation in pancreatic cancer.4 In Europe, regulators began a phased review in July.13

Our assessment

All of the coverage agrees on the core point: drugs can directly target RAS, and doing so roughly doubled median survival in a disease that has seen only small gains for years. The disagreement is mostly about the label and about how far the voucher program should go. In both cases, the FDA chose speed and breadth over narrow precision. For pancreatic cancer, where median survival on second-line chemotherapy was under seven months, the data justify that choice. The program now faces a harder task. It has shown it can approve both obesity drugs and cancer drugs within weeks, and it will be judged on whether those drugs reach patients at prices they can pay and whether the follow-up evidence supports the broad label.